Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | MIF | P14174 | 1/20 | 0.57 |
| ▸ | TYR | P14679 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | ATP2A2 | P16615 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ATP2A3 | Q93084 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29437966 | 1.00 | ALDH1A1 (0.57) | ALDH1A1ALOX15HSD17B10LMNANR1I2 | |
| SCHEMBL18587383 | 0.86 | ALDH1A1 (0.48) | ALDH1A1ALOX15HSD17B10LMNANR1I2 | |
| SCHEMBL11376800 | 0.86 | L3MBTL1 (0.45) | ALDH1A1ALOX15HSD17B10LMNANR1I2 | |
| SCHEMBL8388812 | 0.84 | KDM1A (0.42) | ALDH1A1ALOX15HSD17B10LMNANR1I2 | |
| SCHEMBL23873019 | 0.83 | KIF11 (0.47) | ALDH1A1ALOX15HSD17B10LMNANR1I2 | |
| SCHEMBL11216770 | 0.81 | TRPV4 (0.38) | ALDH1A1ALOX15HSD17B10LMNANR1I2 | |
| SCHEMBL2154684 | 0.81 | KIF11 (0.45) | ALDH1A1ALOX15HSD17B10LMNANR1I2 | |
| SCHEMBL7120216 | 0.80 | P4HB (0.38) | ALDH1A1ALOX15HSD17B10LMNANR1I2 | |
| SCHEMBL6888576 | 0.79 | MEN1 (0.50) | ALDH1A1ALOX15HSD17B10LMNANR1I2 | |
| SCHEMBL29397303 | 0.79 | KIF11 (0.44) | ALDH1A1CYP1A2KIF11TRPV4CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3947365-B1 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | BIONOMICS LTD (AU) | 2025-10-01 | — | — | EP | disclosed |
| US-12139473-B2 | Substituted-N-heteroaryl compounds and uses thereof | BIONOMICS LIMITED (AU) | 2024-11-12 | — | — | US | disclosed |
| US-12090146-B2 | Substituted-pyridinyl compounds and uses thereof | BIONOMICS LIMITED (AU) | 2024-09-17 | — | — | US | disclosed |
| EP-3853216-B1 | 3-[2-(PHENOXY)-4-PYRIDYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES FOR THE TREATMENT OF COGNITIVE DYSFUNCTION AND CNS DISORDERS | BIONOMICS LTD (AU) | 2024-09-11 | — | — | EP | disclosed |
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-07-11 | — | — | US | disclosed |
| US-20230124087-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | disclosed |
| EP-4139306-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | F. Hoffmann-La Roche AG (CH) | 2023-03-01 | — | — | EP | disclosed |
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| CN-115380032-A | KV3 enhancers for the treatment of cognitive disorders | 豪夫迈·罗氏有限公司 | 2022-11-22 | — | — | CN | disclosed |
| US-11352330-B2 | Phenoxymethyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2022-06-07 | — | — | US | disclosed |
| CN-103328467-A | Hydantoin derivatives useful as KV3 inhibitors | AUTIFONY THERAPEUTICS LTD | 2013-09-25 | — | — | CN | disclosed |
| US-20120289526-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2012-11-15 | — | — | US | disclosed |
| US-20120289526-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2012-11-15 | — | — | US | disclosed |
| US-20120289526-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2012-11-15 | — | — | US | disclosed |
| WO-2012076877-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012076877-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
| WO-2011069951-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
| US-7205409-B2 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2007-04-17 | — | — | US | disclosed |
| US-20050131019-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBVIE INC. | 2005-06-16 | — | — | US | disclosed |
| WO-2005023762-A1 | PYRROLIDINE-2-CARBONITRILE DERIVATIVES AND THEIR USE AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131019-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | ALDH1A1 2289/4885ALOX15 2369/4885HSD17B10 621/4885 |
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | KCNN3, KCND3, KCNA3 | ALDH1A1 1966/4885ALOX15 4158/4885HSD17B10 2069/4885 |
| US-11352330-B2 | Phenoxymethyl derivatives | CNKSR1, RB1, RCOR1 | ALDH1A1 131/4885ALOX15 3210/4885HSD17B10 2500/4885 |
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TP53, HRAS, KRAS | ALDH1A1 2917/4885ALOX15 4571/4885HSD17B10 3449/4885 |
| US-12090146-B2 | Substituted-pyridinyl compounds and uses thereof | GABRE, GAP43, GRIN2A | ALDH1A1 3695/4885ALOX15 4155/4885HSD17B10 4334/4885 |
| US-12139473-B2 | Substituted-N-heteroaryl compounds and uses thereof | SCN3A, KCND3, GRIN3A | ALDH1A1 4707/4885ALOX15 4351/4885HSD17B10 3360/4885 |
| US-20230124087-A1 | KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS | KCNN3, KCNA4, KCNA3 | ALDH1A1 2760/4885ALOX15 3408/4885HSD17B10 2534/4885 |
| US-20120289526-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | KCND3, KCNK3, KCNA3 | ALDH1A1 462/4885ALOX15 4155/4885HSD17B10 1973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.